PledPharma Restarts Study with Recipharm CTM

PledPharma has restarted the MANAMI study with the collaboration with Recipharm to ensure new clinical trial material.

Swedish specialty pharma company PledPharma has restarted recruitment on a clinical trial of mangafodipir in treatment outcomes during angioplasty after the company recently gained approval from the Swedish Medical Products Agency for new clinical trial material supplied by Recipharm.

The trial had been suspended last year because of a lack of CTM.

Maria Lundberg, general manager of Recipharm Pharmaceutical Development AB, commented, “We are pleased to contribute to the continuation of this important clinical trial. After being contacted by PledPharma, both companies worked very hard together to get the clinical trial material approved as fast as possible. We are well used to working with tight deadlines and we were very happy with the result that was achieved.”